What is the share price of Onyx Biotec Ltd (ONYX) today?
The share price of ONYX as on 11th July 2025 is ₹49.85. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Onyx Biotec Ltd (ONYX) share?
The past returns of Onyx Biotec Ltd (ONYX) share are- Past 1 week: 2.78%
- Past 1 month: -0.70%
- Past 3 months: -0.30%
- Past 6 months: -38.46%
- Past 1 year: -12.16%
- Past 3 years: N/A%
- Past 5 years: -12.16%
What are the peers or stocks similar to Onyx Biotec Ltd (ONYX)?
The peers or stocks similar to Onyx Biotec Ltd (ONYX) include:What is the market cap of Onyx Biotec Ltd (ONYX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Onyx Biotec Ltd (ONYX) is ₹90.39 Cr as of 11th July 2025.What is the 52 week high and low of Onyx Biotec Ltd (ONYX) share?
The 52-week high of Onyx Biotec Ltd (ONYX) is ₹97.45 and the 52-week low is ₹45.What is the PE and PB ratio of Onyx Biotec Ltd (ONYX) stock?
The P/E (price-to-earnings) ratio of Onyx Biotec Ltd (ONYX) is 18.26. The P/B (price-to-book) ratio is 3.63.Which sector does Onyx Biotec Ltd (ONYX) belong to?
Onyx Biotec Ltd (ONYX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Onyx Biotec Ltd (ONYX) shares?
You can directly buy Onyx Biotec Ltd (ONYX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Onyx Biotec Ltd
ONYX Share Price
ONYX Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ONYX Performance & Key Metrics
ONYX Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
— | 3.63 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.72 | 6.42 | 0.79% |
ONYX Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
ONYX Company Profile
Onyx Biotec Ltd. is a pharmaceutical company focused on the manufacture, sale, and distribution of generic and proprietary pharmaceutical products, including sterile water for injection and various dry powder injections and syrups.
ONYX Forecast
ONYX Forecasts
ONYX
ONYX
Income
Balance Sheet
Cash Flow
ONYX Income Statement
ONYX Income Statement
Financial Year | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||
---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 44.98 | 39.61 | 53.88 | 63.12 | — | |||||
Raw Materials | 26.47 | 21.30 | 36.17 | 51.61 | — | |||||
Power & Fuel Cost | 0.00 | 0.00 | 0.00 | |||||||
Employee Cost | 8.62 | 10.48 | 6.00 | |||||||
Selling & Administrative Expenses | 2.06 | 1.76 | 2.08 | |||||||
Operating & Other expenses | 1.94 | 1.46 | 1.16 | |||||||
EBITDA | 5.89 | 4.61 | 8.47 | 11.51 | — | |||||
Depreciation/Amortization | 1.45 | 1.49 | 2.25 | 3.05 | — | |||||
PBIT | 4.44 | 3.12 | 6.22 | 8.46 | — | |||||
Interest & Other Items | 0.65 | 0.57 | 2.16 | 1.99 | — | |||||
PBT | 3.79 | 2.55 | 4.06 | 6.47 | — | |||||
Taxes & Other Items | 0.44 | 0.70 | 1.02 | 1.52 | — | |||||
Net Income | 3.35 | 1.85 | 3.04 | 4.95 | — | |||||
EPS | 2.84 | 1.57 | 2.42 | 3.30 | — | |||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | — |
ONYX Company Updates
ONYX Stock Peers
ONYX Past Performance & Peer Comparison
ONYX Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Onyx Biotec Ltd | 18.26 | 3.63 | — |
Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
Cipla Ltd | 22.75 | 3.83 | 1.08% |
Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
ONYX Stock Price Comparison
Compare ONYX with any stock or ETFONYX Holdings
ONYX Shareholdings
ONYX Promoter Holdings Trend
ONYX Promoter Holdings Trend
ONYX Institutional Holdings Trend
ONYX Institutional Holdings Trend
No institutional holdings trend are available
ONYX Shareholding Pattern
ONYX Shareholding Pattern
ONYX Shareholding History
ONYX Shareholding History
smallcases containing ONYX stock
smallcases containing ONYX stock
Looks like this stock is not in any smallcase yet.
ONYX Events
ONYX Events
ONYX Dividend Trend
ONYX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
ONYX Dividend Trend
ONYX has not given any dividends in last 5 years
ONYX Dividends
ONYX Dividends
ONYX Stock News & Opinions
ONYX Stock News & Opinions
Onyx biotec will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
The scrip was listed at Rs 54.05, a discount of 11.39% over the initial public offer (IPO) price. The stock was currently frozen at its upper limit of 5% compared to its listing price. The counter hit a high of Rs 56.75 and a low of Rs 51.45. About 6.52 lakh shares of the company changed hands at the counter. Onyx Biotec's IPO was subscribed 184.60 times. The issue opened for bidding on 13 November 2024 and it closed on 18 November 2024. The price band of the IPO was set at Rs 58 to Rs 61 per share. The IPO comprised fresh issue of 48,10,000 shares. The promoter and promoter group shareholding diluted to 65.10% from 88.60% pre-IPO. The company intends to utilize the net proceeds for up gradation of existing manufacturing unit I to manufacture large volume parental for intravenous use, setting up a high-speed cartooning packaging line at existing manufacturing unit II for dry powder injections, prepayment or repayment of all or a portion of certain loans availed by company and for general corporate purpose. Ahead of the IPO, Onyx Biotec on 12 November 2024, raised Rs 8.33 crore from anchor investors. The board allotted 13.66 lakh shares at Rs 61 per share to 3 anchor investor. Onyx Biotec is a pharmaceutical company providing sterile water for injections. The company currently manufactures sterile water for injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of dry powder injections and dry syrups for both the Indian and overseas markets. The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift. As of 31 July 2024, the company had 175 employees on payroll The company recorded revenue from operations of Rs 10.52 crore and net profit of Rs 1.30 crore for the period as on 31 May 2024. Powered by Capital Market - Live
Pledged promoter holdings is insignificant